Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 1835667-63-4
2. Unii-0xt2cpr891
3. Befotertinib [inn]
4. 0xt2cpr891
5. Surmana
6. D-0316
7. N-[2-[2-(dimethylamino)ethyl-methylamino]-4-methoxy-5-[[4-[1-(2,2,2-trifluoroethyl)indol-3-yl]pyrimidin-2-yl]amino]phenyl]prop-2-enamide
8. D0316
9. 2-propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-(2,2,2-trifluoroethyl)-1h-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-
10. N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-(2,2,2-trifluoroethyl)-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)prop-2-enamide
11. Compound 4 [wo2019218987a1]
12. D 0316
13. Compound 4 (wo2019218987a1)
14. N-(2-(2-(dimethylamino)ethyl-methylamino)-4-methoxy-5-((4-(1-(2,2,2-trifluoroethyl)indol-3-yl)pyrimidin-2-yl)amino)phenyl)prop-2-enamide
15. Refchem:116874
16. D-0316 [who-dd]
17. Befotertinib [who-dd]
18. Orb1303551
19. Chembl5095167
20. Schembl19337178
21. Schembl29774263
22. Schembl30595515
23. Gtpl12951
24. Usoczvzoxktjti-uhfffaoysa-n
25. Glxc-26863
26. Akos040757081
27. Da-71363
28. Ms-30266
29. Hy-137433
30. Cs-0138633
31. F78035
32. N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-(2,2,2-trifluoroethyl)-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide
| Molecular Weight | 567.6 g/mol |
|---|---|
| Molecular Formula | C29H32F3N7O2 |
| XLogP3 | 4.8 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 11 |
| Exact Mass | Da |
| Monoisotopic Mass | Da |
| Topological Polar Surface Area | 87.6 |
| Heavy Atom Count | 41 |
| Formal Charge | 0 |
| Complexity | 863 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
ABOUT THIS PAGE
75
PharmaCompass offers a list of Befotertinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Befotertinib manufacturer or Befotertinib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Befotertinib manufacturer or Befotertinib supplier.
A Befotertinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Befotertinib, including repackagers and relabelers. The FDA regulates Befotertinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Befotertinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Befotertinib supplier is an individual or a company that provides Befotertinib active pharmaceutical ingredient (API) or Befotertinib finished formulations upon request. The Befotertinib suppliers may include Befotertinib API manufacturers, exporters, distributors and traders.
Befotertinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Befotertinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Befotertinib GMP manufacturer or Befotertinib GMP API supplier for your needs.
A Befotertinib CoA (Certificate of Analysis) is a formal document that attests to Befotertinib's compliance with Befotertinib specifications and serves as a tool for batch-level quality control.
Befotertinib CoA mostly includes findings from lab analyses of a specific batch. For each Befotertinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Befotertinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Befotertinib EP), Befotertinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Befotertinib USP).
